| Identification | Back Directory | [Name]
Ulodesine | [CAS]
548486-59-5 | [Synonyms]
Ulodesine
Evenamide Hydrochloride
7-(((3R,4R)-3-Hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl)methyl)-1H-pyrrolo[3,2-d]pyrimidin-4(5H)-one
4H-Pyrrolo[3,2-d]pyrimidin-4-one, 3,5-dihydro-7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-pyrrolidinyl]methyl]- | [Molecular Formula]
C12H16N4O3 | [MDL Number]
MFCD28502209 | [MOL File]
548486-59-5.mol | [Molecular Weight]
264.28 |
| Chemical Properties | Back Directory | [Melting point ]
248-250 °C | [Boiling point ]
526.9±60.0 °C(Predicted) | [density ]
1.68±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 25 mg/mL (94.60 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
14.55±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Ulodesine is a purine nucleoside phosphorylase (PNP) inhibitor. Ulodesine inhibits PNP with IC50 value of 2.293 nM/L. Ulodesine can be used for the research of hyporucicemia[1][2]. | [in vivo]
Ulodesine (i.v.) potently inhibits PNP with IC50 value of 2.293 nM/L[1].
Ulodesine (i.v.) eliminates uric acid accumulations in blood of the mouse model[1]. | [References]
[1] Xujuan YANG, et al. Establishment of a novel hyperuricemiaanimal model using mice and assessment ofhyporuricemia action of PNP inhibitor Ulodesine.
[2] Cesar Diaz-Torné, et al. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015 Mar;27(2):164-9. DOI:10.1097/BOR.0000000000000146 |
|
|